Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

CAR Natural Killer Cells Show Promise in Patients With CLL, NHL

04/19/2020

Katy Rezvani, MD, PhD, discusses the use of CAR natural killer cells in patients with non-Hodgkin’s lymphoma or CLL.

Katy Rezvani, MD, PhD, discusses...

04/19/2020

Oncology

Interview

Richter Transformation Tied to Poor Prognosis, High Death Rate in Patients With CLL

04/16/2020

Othman Al-Sawaf, MD, discusses a pooled analysis evaluating the incidence, characteristics, and outcomes of patients with CLL and Richter transformation.

Othman Al-Sawaf, MD, discusses a...

04/16/2020

Oncology

Videos

Novel Therapeutic Approaches in CLL

03/07/2020

Michael Choi, MD, discusses novel approaches for the treatment of patients with CLL.

Michael Choi, MD, discusses...

03/07/2020

Oncology

Podcasts

Non-Chemotherapy Approach Induces High Rate of Undetectable MRD in CLL

02/27/2020

Nitin Jain, MD, discusses results from a trial exploring the combination of ibrutinib and venetoclax for patients with relapsed/refractory CLL.

Nitin Jain, MD, discusses...

02/27/2020

Oncology

Podcasts

Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age

02/20/2020

Nitin Jain, MD, discusses results from a trial exploring the combination of ibrutinib and venetoclax as first-line treatment for CLL.

Nitin Jain, MD, discusses...

02/20/2020

Oncology

Podcasts

iFCG Regimen Effective for Young, Fit Patients With IGHV-Mutated CLL

02/07/2020

Nitin Jain, MD, discusses results from a phase 2 study exploring a treatment regimen consisting of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for patients with IGHV‑mutated CLL.

Nitin Jain, MD, discusses...

02/07/2020

Oncology

Podcasts

Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL

02/02/2020

Jeff Sharman, MD, discusses results from the ELEVATE TN trial, which led to the FDA approval of acalabrutinib for the management of patients with treatment-naïve CLL.

Jeff Sharman, MD, discusses...

02/02/2020

Oncology

Videos

Immune Function in CLL: What’s Wrong and Why?

01/21/2020

Neil Kay, MD, discusses immune deficiency in CLL and certain complications that physicians can face when treating patients with this disease.

Neil Kay, MD, discusses immune...

01/21/2020

Oncology

Videos

Ibrutinib Plus Rituximab Yields Significant PFS Benefit Over FCR for CLL

01/12/2020

Neil Kay, MD, discusses results from the E1912 trial, which showed a significant PFS benefit with ibrutinib plus rituximab over standard FCR in CLL.

Neil Kay, MD, discusses results...

01/12/2020

Oncology

Videos

Novel Agents for Treating Older Patients With CLL

11/13/2019

Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.

Jennifer Woyach, MD, discusses...

11/13/2019

Oncology

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products